British medical journal Lancet published a new research today. Taking low-dose aspirin for years might reduce the chance of dying from cancer. Eight previous studies were reviewed for this research. All told, about 25,500 patients’ details was included. This research is incredibly encouraging. There aren’t yet enough data for doctors for making a decision on aspirin therapy. Article resource – Study links aspirin and cancer survival – don’t start pills yet by Money Blog Newz.
Cancer risks going down with aspirin
The meta-study published today was completed by a team of British researchers. They found that 75 milligrams of aspirin taken daily for five years or more reduces the risk of dying from cancer. Deaths from lung and prostate cancer were decreased about 20 percent, gastrointestinal cancers by 54 percent and esophageal cancers by 60 percent. Between 5 and 20 years were the daily low-dose aspirin taken. The cardiovascular effects while taking day-to-day aspirin was the original purpose of the study.
Not suggesting day-to-day aspirin
Though the research shows significant and dramatic improvement within the prospect of surviving some cancers, the researchers do not yet recommend it as a daily regimen. "Proof of principle" needs to be found with more studies. Also, the meta-study only had a few subjects in it. It would be relatively safe to take aspirin daily. Of course, ringing in the ears, loss of balance, heartburn and thinning of blood can take place with it too. ”I definitely think we wouldn’t want for making any treatment decisions depending on this research,” according to the provost of the University of Texas M.D. Anderson Cancer Center Dr. Raymond DuBois. Dr. Raymond DuBois said, “I certainly think we wouldn’t want to make any treatment decisions based on this research." He is from the University of Tex! as M.D. Anderson Cancer Center.
Difficulties to check out first with aspirin-cancer study
There were 2 studies done that showed an improved cancer survival rate with aspirin. Or course, the same group of researchers in Britain did both of the studies. The studies are not complete though. There are gaps in them. Only 33 percent were women in the main meta-analysis. That is out of 25,000 subjects. There was no data on less common cancers like brain and stomach. The low-dose aspirin might not work on them. There is also an issue caused by the research at first being done to study the use of aspirin on the heart. The patients might be skewed a bit.
The use of aspirin on cancer may be something really exciting to start working with. Unfortunately, it is not something that you should start trying as there isn't nearly enough research in it to say it works or is safe.
Citations
Washington Post
washingtonpost.com/wp-dyn/content/article/2010/12/07/AR2010120701602.html
Business Week
businessweek.com/lifestyle/content/healthday/647054.html
No comments:
Post a Comment